APO Research
Talk to an analyst

APO RESEARCH · REPORT

HER2 Antibody

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global HER2 Antibody Market Outlook and Growth Opportunities 2026

26 December 2025191 pages

Choose your research edition.

Industry ResearchHER2 Antibody Industry Research Report 2026110 pages · $2,950 USDIndustry Growth & TrendsGlobal HER2 Antibody Industry Growth and Trends Forecast to 203289 pages · $3,450 USDMarket StructureGlobal HER2 Antibody Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032189 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal HER2 Antibody Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal HER2 Antibody Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

The global HER2 Antibody market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for HER2 Antibody is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for HER2 Antibody is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for HER2 Antibody is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the HER2 Antibody market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the HER2 Antibody market include Novartis AG, Pfizer, InvivoGen, Genentech Inc, Celltrion, Bio-Techne, Biocon Limited and Abnova Corporation, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global HER2 Antibody market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of HER2 Antibody and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents HER2 Antibody revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global HER2 Antibody market.

HER2 Antibody Segment by Company

Novartis AG

Pfizer

InvivoGen

Genentech Inc

Celltrion

Bio-Techne

Biocon Limited

Abnova Corporation

HER2 Antibody Segment by Type

Ado-trastuzumab Emtansine

Lapatinib

Pertuzumab

Trastuzumab

Everolimus

HER2 Antibody Segment by Application

Hospital

Medical Center

HER2 Antibody Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global HER2 Antibody status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the HER2 Antibody key companies, revenue, market share, and recent developments.

3. To split the HER2 Antibody breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions HER2 Antibody market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify HER2 Antibody significant trends, drivers, influence factors in global and regions.

6. To analyze HER2 Antibody competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global HER2 Antibody market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of HER2 Antibody and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of HER2 Antibody.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global HER2 Antibody industry.

Chapter 3: Detailed analysis of HER2 Antibody company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of HER2 Antibody in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of HER2 Antibody in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. HER2 Antibody Industry Trends Table 2. HER2 Antibody Industry Drivers Table 3. HER2 Antibody Industry Opportunities and Challenges Table 4. HER2 Antibody Industry Restraints Table 5. Global HER2 Antibody Revenue by Company (US$ Million) & (2021-2026) Table 6. Global HER2 Antibody Revenue Share by Company (2021-2026) Table 7. Global HER2 Antibody Company Ranking, (2024-2026) & (US$ Million) Table 8. Global HER2 Antibody Key Company Manufacturing Base & Headquarters Table 9. Global HER2 Antibody Company, Product Type & Application Table 10. Global HER2 Antibody Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global HER2 Antibody by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Ado-trastuzumab Emtansine Table 15. Significant Companies of Lapatinib Table 16. Significant Companies of Pertuzumab Table 17. Significant Companies of Trastuzumab Table 18. Significant Companies of Everolimus Table 19. Global HER2 Antibody Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 20. Global HER2 Antibody Sales Value by Type (2021-2026) & (US$ Million) Table 21. Global HER2 Antibody Sales Value by Type (2027-2032) & (US$ Million) Table 22. Global HER2 Antibody Sales Value Share by Type (2021-2026) Table 23. Global HER2 Antibody Sales Value Share by Type (2027-2032) Table 24. Significant Companies of Hospital Table 25. Significant Companies of Medical Center Table 26. Global HER2 Antibody Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global HER2 Antibody Sales Value by Application (2021-2026) & (US$ Million) Table 28. Global HER2 Antibody Sales Value by Application (2027-2032) & (US$ Million) Table 29. Global HER2 Antibody Sales Value Share by Application (2021-2026) Table 30. Global HER2 Antibody Sales Value Share by Application (2027-2032) Table 31. Global HER2 Antibody Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global HER2 Antibody Sales Value by Region (2021-2026) & (US$ Million) Table 33. Global HER2 Antibody Sales Value Share by Region (2021-2026) Table 34. Global HER2 Antibody Sales Value by Region (2027-2032) & (US$ Million) Table 35. Global HER2 Antibody Sales Value Share by Region (2027-2032) Table 36. Global HER2 Antibody Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global HER2 Antibody Sales Value by Country (2021-2026) & (US$ Million) Table 38. Global HER2 Antibody Sales Value Market Share by Country (2021-2026) Table 39. Global HER2 Antibody Sales Value by Country (2027-2032) & (US$ Million) Table 40. Global HER2 Antibody Sales Value Market Share by Country (2027-2032) Table 41. Novartis AG Company Information Table 42. Novartis AG Business Overview Table 43. Novartis AG HER2 Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 44. Novartis AG HER2 Antibody Product Portfolio Table 45. Novartis AG Recent Development Table 46. Pfizer Company Information Table 47. Pfizer Business Overview Table 48. Pfizer HER2 Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 49. Pfizer HER2 Antibody Product Portfolio Table 50. Pfizer Recent Development Table 51. InvivoGen Company Information Table 52. InvivoGen Business Overview Table 53. InvivoGen HER2 Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 54. InvivoGen HER2 Antibody Product Portfolio Table 55. InvivoGen Recent Development Table 56. Genentech Inc Company Information Table 57. Genentech Inc Business Overview Table 58. Genentech Inc HER2 Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 59. Genentech Inc HER2 Antibody Product Portfolio Table 60. Genentech Inc Recent Development Table 61. Celltrion Company Information Table 62. Celltrion Business Overview Table 63. Celltrion HER2 Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 64. Celltrion HER2 Antibody Product Portfolio Table 65. Celltrion Recent Development Table 66. Bio-Techne Company Information Table 67. Bio-Techne Business Overview Table 68. Bio-Techne HER2 Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. Bio-Techne HER2 Antibody Product Portfolio Table 70. Bio-Techne Recent Development Table 71. Biocon Limited Company Information Table 72. Biocon Limited Business Overview Table 73. Biocon Limited HER2 Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. Biocon Limited HER2 Antibody Product Portfolio Table 75. Biocon Limited Recent Development Table 76. Abnova Corporation Company Information Table 77. Abnova Corporation Business Overview Table 78. Abnova Corporation HER2 Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. Abnova Corporation HER2 Antibody Product Portfolio Table 80. Abnova Corporation Recent Development Table 81. Research Programs/Design for This Report Table 82. Authors List of This Report Table 83. Secondary Sources Table 84. Primary Sources List of Figures Figure 1. HER2 Antibody Product Image Figure 2. Global HER2 Antibody Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global HER2 Antibody Market Size (2021-2032) & (US$ Million) Figure 4. Global HER2 Antibody Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Ado-trastuzumab Emtansine Image Figure 8. Lapatinib Image Figure 9. Pertuzumab Image Figure 10. Trastuzumab Image Figure 11. Everolimus Image Figure 12. Global HER2 Antibody Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 13. Global HER2 Antibody Sales Value Share 2021 VS 2025 VS 2032 Figure 14. Global HER2 Antibody Sales Value Share by Type (2021-2032) Figure 15. Hospital Image Figure 16. Medical Center Image Figure 17. Global HER2 Antibody Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global HER2 Antibody Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global HER2 Antibody Sales Value Share by Application (2021-2032) Figure 20. Global HER2 Antibody Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 21. Global HER2 Antibody Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 22. North America HER2 Antibody Sales Value (2021-2032) & (US$ Million) Figure 23. North America HER2 Antibody Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Europe HER2 Antibody Sales Value (2021-2032) & (US$ Million) Figure 25. Europe HER2 Antibody Sales Value Share by Country (%), 2025 VS 2032 Figure 26. Asia-Pacific HER2 Antibody Sales Value (2021-2032) & (US$ Million) Figure 27. Asia-Pacific HER2 Antibody Sales Value Share by Country (%), 2025 VS 2032 Figure 28. South America HER2 Antibody Sales Value (2021-2032) & (US$ Million) Figure 29. South America HER2 Antibody Sales Value Share by Country (%), 2025 VS 2032 Figure 30. Middle East & Africa HER2 Antibody Sales Value (2021-2032) & (US$ Million) Figure 31. Middle East & Africa HER2 Antibody Sales Value Share by Country (%), 2025 VS 2032 Figure 32. USA HER2 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 33. USA HER2 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 34. USA HER2 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 35. Canada HER2 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. Canada HER2 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. Canada HER2 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Mexico HER2 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Mexico HER2 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Mexico HER2 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. Germany HER2 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. Germany HER2 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. Germany HER2 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. France HER2 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. France HER2 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. France HER2 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. U.K. HER2 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. U.K. HER2 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. U.K. HER2 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Italy HER2 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Italy HER2 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Italy HER2 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Spain HER2 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Spain HER2 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Spain HER2 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Russia HER2 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Russia HER2 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Russia HER2 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Netherlands HER2 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Netherlands HER2 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Netherlands HER2 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Nordic Countries HER2 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Nordic Countries HER2 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Nordic Countries HER2 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. China HER2 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. China HER2 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. China HER2 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Japan HER2 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Japan HER2 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Japan HER2 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. South Korea HER2 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. South Korea HER2 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. South Korea HER2 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. India HER2 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. India HER2 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. India HER2 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Australia HER2 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Australia HER2 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Australia HER2 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Southeast Asia HER2 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Southeast Asia HER2 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Southeast Asia HER2 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Brazil HER2 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Brazil HER2 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Brazil HER2 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Argentina HER2 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Argentina HER2 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Argentina HER2 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Chile HER2 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Chile HER2 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Chile HER2 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Colombia HER2 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Colombia HER2 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Colombia HER2 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Peru HER2 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Peru HER2 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Peru HER2 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Saudi Arabia HER2 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Saudi Arabia HER2 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Saudi Arabia HER2 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Israel HER2 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Israel HER2 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Israel HER2 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. UAE HER2 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. UAE HER2 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. UAE HER2 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Turkey HER2 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Turkey HER2 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Turkey HER2 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Iran HER2 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Iran HER2 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Iran HER2 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Egypt HER2 Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Egypt HER2 Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Egypt HER2 Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Years Considered Figure 117. Research Process Figure 118. Key Executives Interviewed

Scope & coverage.

Types
  • Ado-trastuzumab Emtansine
  • Lapatinib
  • Pertuzumab
  • Trastuzumab
  • Everolimus
Applications
  • Hospital
  • Medical Center
Companies covered
  • Novartis AG
  • Pfizer
  • InvivoGen
  • Genentech Inc
  • Celltrion
  • Bio-Techne
  • Biocon Limited
  • Abnova Corporation

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global HER2 Antibody Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global HER2 Antibody Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 HER2 Antibody Market Dynamics
  1. 2.1 HER2 Antibody Industry Trends
  2. 2.2 HER2 Antibody Industry Drivers
  3. 2.3 HER2 Antibody Industry Opportunities and Challenges
  4. 2.4 HER2 Antibody Industry Restraints
3 HER2 Antibody Market by Company
  1. 3.1 Global HER2 Antibody Company Revenue Ranking in 2025
  2. 3.2 Global HER2 Antibody Revenue by Company (2021-2026)
  3. 3.3 Global HER2 Antibody Company Ranking (2024-2026)
  4. 3.4 Global HER2 Antibody Company Manufacturing Base and Headquarters
  5. 3.5 Global HER2 Antibody Company Product Type and Application
  6. 3.6 Global HER2 Antibody Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global HER2 Antibody Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 HER2 Antibody Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 HER2 Antibody Market by Type
  1. 4.1 HER2 Antibody Type Introduction
  2. 4.1.1 Ado-trastuzumab Emtansine
  3. 4.1.2 Lapatinib
  4. 4.1.3 Pertuzumab
  5. 4.1.4 Trastuzumab
  6. 4.1.5 Everolimus
  7. 4.2 Global HER2 Antibody Sales Value by Type
  8. 4.2.1 Global HER2 Antibody Sales Value by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global HER2 Antibody Sales Value by Type (2021-2032)
  10. 4.2.3 Global HER2 Antibody Sales Value Share by Type (2021-2032)
5 HER2 Antibody Market by Application
  1. 5.1 HER2 Antibody Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Medical Center
  4. 5.2 Global HER2 Antibody Sales Value by Application
  5. 5.2.1 Global HER2 Antibody Sales Value by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global HER2 Antibody Sales Value by Application (2021-2032)
  7. 5.2.3 Global HER2 Antibody Sales Value Share by Application (2021-2032)
6 HER2 Antibody Regional Value Analysis
  1. 6.1 Global HER2 Antibody Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global HER2 Antibody Sales Value by Region (2021-2032)
  3. 6.2.1 Global HER2 Antibody Sales Value by Region: 2021-2026
  4. 6.2.2 Global HER2 Antibody Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America HER2 Antibody Sales Value (2021-2032)
  7. 6.3.2 North America HER2 Antibody Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe HER2 Antibody Sales Value (2021-2032)
  10. 6.4.2 Europe HER2 Antibody Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific HER2 Antibody Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific HER2 Antibody Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America HER2 Antibody Sales Value (2021-2032)
  16. 6.6.2 South America HER2 Antibody Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa HER2 Antibody Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa HER2 Antibody Sales Value Share by Country, 2025 VS 2032
7 HER2 Antibody Country-level Value Analysis
  1. 7.1 Global HER2 Antibody Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global HER2 Antibody Sales Value by Country (2021-2032)
  3. 7.2.1 Global HER2 Antibody Sales Value by Country (2021-2026)
  4. 7.2.2 Global HER2 Antibody Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA HER2 Antibody Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA HER2 Antibody Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA HER2 Antibody Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada HER2 Antibody Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada HER2 Antibody Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada HER2 Antibody Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico HER2 Antibody Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico HER2 Antibody Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico HER2 Antibody Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany HER2 Antibody Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany HER2 Antibody Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany HER2 Antibody Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France HER2 Antibody Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France HER2 Antibody Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France HER2 Antibody Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. HER2 Antibody Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. HER2 Antibody Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. HER2 Antibody Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy HER2 Antibody Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy HER2 Antibody Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy HER2 Antibody Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain HER2 Antibody Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain HER2 Antibody Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain HER2 Antibody Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia HER2 Antibody Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia HER2 Antibody Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia HER2 Antibody Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands HER2 Antibody Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands HER2 Antibody Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands HER2 Antibody Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries HER2 Antibody Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries HER2 Antibody Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries HER2 Antibody Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China HER2 Antibody Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China HER2 Antibody Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China HER2 Antibody Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan HER2 Antibody Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan HER2 Antibody Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan HER2 Antibody Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea HER2 Antibody Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea HER2 Antibody Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea HER2 Antibody Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India HER2 Antibody Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India HER2 Antibody Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India HER2 Antibody Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia HER2 Antibody Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia HER2 Antibody Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia HER2 Antibody Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia HER2 Antibody Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia HER2 Antibody Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia HER2 Antibody Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil HER2 Antibody Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil HER2 Antibody Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil HER2 Antibody Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina HER2 Antibody Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina HER2 Antibody Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina HER2 Antibody Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile HER2 Antibody Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile HER2 Antibody Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile HER2 Antibody Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia HER2 Antibody Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia HER2 Antibody Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia HER2 Antibody Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru HER2 Antibody Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru HER2 Antibody Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru HER2 Antibody Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia HER2 Antibody Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia HER2 Antibody Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia HER2 Antibody Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel HER2 Antibody Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel HER2 Antibody Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel HER2 Antibody Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE HER2 Antibody Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE HER2 Antibody Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE HER2 Antibody Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey HER2 Antibody Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey HER2 Antibody Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey HER2 Antibody Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran HER2 Antibody Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran HER2 Antibody Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran HER2 Antibody Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt HER2 Antibody Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt HER2 Antibody Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt HER2 Antibody Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Novartis AG
  2. 8.1.1 Novartis AG Company Information
  3. 8.1.2 Novartis AG Business Overview
  4. 8.1.3 Novartis AG HER2 Antibody Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Novartis AG HER2 Antibody Product Portfolio
  6. 8.1.5 Novartis AG Recent Developments
  7. 8.2 Pfizer
  8. 8.2.1 Pfizer Company Information
  9. 8.2.2 Pfizer Business Overview
  10. 8.2.3 Pfizer HER2 Antibody Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Pfizer HER2 Antibody Product Portfolio
  12. 8.2.5 Pfizer Recent Developments
  13. 8.3 InvivoGen
  14. 8.3.1 InvivoGen Company Information
  15. 8.3.2 InvivoGen Business Overview
  16. 8.3.3 InvivoGen HER2 Antibody Revenue and Gross Margin (2021-2026)
  17. 8.3.4 InvivoGen HER2 Antibody Product Portfolio
  18. 8.3.5 InvivoGen Recent Developments
  19. 8.4 Genentech Inc
  20. 8.4.1 Genentech Inc Company Information
  21. 8.4.2 Genentech Inc Business Overview
  22. 8.4.3 Genentech Inc HER2 Antibody Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Genentech Inc HER2 Antibody Product Portfolio
  24. 8.4.5 Genentech Inc Recent Developments
  25. 8.5 Celltrion
  26. 8.5.1 Celltrion Company Information
  27. 8.5.2 Celltrion Business Overview
  28. 8.5.3 Celltrion HER2 Antibody Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Celltrion HER2 Antibody Product Portfolio
  30. 8.5.5 Celltrion Recent Developments
  31. 8.6 Bio-Techne
  32. 8.6.1 Bio-Techne Company Information
  33. 8.6.2 Bio-Techne Business Overview
  34. 8.6.3 Bio-Techne HER2 Antibody Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Bio-Techne HER2 Antibody Product Portfolio
  36. 8.6.5 Bio-Techne Recent Developments
  37. 8.7 Biocon Limited
  38. 8.7.1 Biocon Limited Company Information
  39. 8.7.2 Biocon Limited Business Overview
  40. 8.7.3 Biocon Limited HER2 Antibody Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Biocon Limited HER2 Antibody Product Portfolio
  42. 8.7.5 Biocon Limited Recent Developments
  43. 8.8 Abnova Corporation
  44. 8.8.1 Abnova Corporation Company Information
  45. 8.8.2 Abnova Corporation Business Overview
  46. 8.8.3 Abnova Corporation HER2 Antibody Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Abnova Corporation HER2 Antibody Product Portfolio
  48. 8.8.5 Abnova Corporation Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst